PTC Therapeutics, Inc. (PTCT) is a Biotechnology company in the Healthcare sector, currently trading at $73.01. It has a SharesGrow Score of 74/100, indicating a above average investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PTCT = $142.35 (+95% from the current price, the stock appears undervalued). Analyst consensus target is PTCT = $85 (+15.7% upside).
Valuation: PTCT trades at a trailing Price-to-Earnings (P/E) of 8.4 (S&P 500 average ~25).
Financials: revenue is $1.7B, +44.9%/yr average growth. Net income is $683M, growing at +105.9%/yr. Net profit margin is 39.4% (strong). Gross margin is 95.9% (+2.3 pp trend).
Balance sheet: total debt is $492M with negative equity of -$205M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 2.35 (strong liquidity). Debt-to-assets is 16.9%. Total assets: $2.9B.
Analyst outlook: 15 / 26 analysts rate PTCT as buy (58%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 86/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 75/100 (Pass), Moat 74/100 (Pass), Future 58/100 (Partial), Income 100/100 (Pass).
